Trials & Tribulations Cancer AI systems: We need oncologists to help us build trusted models March 01, 2024Vol.50 No.09By Bernard Chien
First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
Trials & Tribulations Florez Laboratory at Dana-Farber launches International Pregnancy and Lung Cancer Registry February 09, 2024Vol.50 No.06By Narjust Florez, Lauren Keil, Rebekah Kaufman and Oyepeju Abioye-Akintola
FDA, Friends identify next steps for dose optimization, pragmatic trials, academic-led studies for drug approvals December 15, 2023Vol.49 No.46By Matthew Bin Han Ong
ESMO discussants urge physicians to prescribe lower dose of Amgen’s sotorasib November 17, 2023Vol.49 No.43By Paul Goldberg
After revolutionizing treatment of blood cancers, imatinib stands poised to eradicate malaria November 03, 2023Vol.49 No.41By Jacquelyn Cobb
Real-world Evidence Real-world tumor response rate can serve as a clinical endpoint, Friends pilot study showsFDA says raw images enrich the data when used with clinician assessments October 06, 2023Vol.49 No.37By Matthew Bin Han Ong
ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution” September 29, 2023Vol.49 No.36By Jacquelyn Cobb
Carolyn Bertozzi focused on bioorthogonal chemistry in 1996 and won the Nobel Prize in 2022This is how her discovery got to cancer clinical trials July 28, 2023Vol.49 No.30By Jacquelyn Cobb
Conversation with The Cancer Letter Nobel Prize-winning technology may enable delivery of up to 12x the standard doxorubicin dose July 28, 2023Vol.49 No.30By Jacquelyn Cobb
